1. Home
  2. CBIO vs PTNM Comparison

CBIO vs PTNM Comparison

Compare CBIO & PTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • PTNM
  • Stock Information
  • Founded
  • CBIO 2003
  • PTNM 2013
  • Country
  • CBIO United States
  • PTNM Hong Kong
  • Employees
  • CBIO N/A
  • PTNM N/A
  • Industry
  • CBIO
  • PTNM
  • Sector
  • CBIO
  • PTNM
  • Exchange
  • CBIO Nasdaq
  • PTNM Nasdaq
  • Market Cap
  • CBIO 308.0M
  • PTNM 320.2M
  • IPO Year
  • CBIO N/A
  • PTNM 2025
  • Fundamental
  • Price
  • CBIO $14.29
  • PTNM $1.85
  • Analyst Decision
  • CBIO Strong Buy
  • PTNM
  • Analyst Count
  • CBIO 5
  • PTNM 0
  • Target Price
  • CBIO $25.60
  • PTNM N/A
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • PTNM 3.3M
  • Earning Date
  • CBIO 07-31-2025
  • PTNM 01-01-0001
  • Dividend Yield
  • CBIO N/A
  • PTNM N/A
  • EPS Growth
  • CBIO N/A
  • PTNM N/A
  • EPS
  • CBIO N/A
  • PTNM 0.05
  • Revenue
  • CBIO N/A
  • PTNM $9,644,233.00
  • Revenue This Year
  • CBIO N/A
  • PTNM N/A
  • Revenue Next Year
  • CBIO N/A
  • PTNM N/A
  • P/E Ratio
  • CBIO N/A
  • PTNM $32.65
  • Revenue Growth
  • CBIO N/A
  • PTNM 9.87
  • 52 Week Low
  • CBIO $10.83
  • PTNM $0.98
  • 52 Week High
  • CBIO $21.40
  • PTNM $14.79
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • PTNM N/A
  • Support Level
  • CBIO $13.50
  • PTNM N/A
  • Resistance Level
  • CBIO $16.00
  • PTNM N/A
  • Average True Range (ATR)
  • CBIO 0.79
  • PTNM 0.00
  • MACD
  • CBIO 0.16
  • PTNM 0.00
  • Stochastic Oscillator
  • CBIO 39.68
  • PTNM 0.00

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About PTNM Pitanium Limited Class A Ordinary shares

Pitanium Ltd is a retailer in Hong Kong focusing on the sale of its proprietary brand of skincare and personal care products, especially haircare products, namely PITANIUM and BIG PI online and offline with six retail stores situated in Prime shopping destinations in Hong Kong. The company emphasizes product design and development with an in-house product development team working closely with its original equipment manufacturing (OEM) and original design manufacturing (ODM) suppliers.

Share on Social Networks: